Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA MAPK13
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
siRNA MAPK13 is a small interfering RNA (siRNA) designed to selectively silence the expression of Mitogen-activated protein kinase 13 (MAPK13), also known as p38 delta. MAPK13 is a member of the p38 MAPK family and has been identified as a key regulator of mucus production (specifically MUC5AC) and airway epithelial barrier integrity in the context of respiratory diseases like asthma. Research indicates that silencing MAPK13 can reduce mucus hypersecretion and impact transepithelial electrical resistance (TEER) in response to stimuli such as IL-13 and LPS. It is currently being investigated as a potential therapeutic target for asthma and other inflammatory airway diseases.
- Other names
- MAPK13 siRNAMAPK-13 siRNAMAPK 13 siRNA
02
Targets
PRR (Pattern recognition receptors)MAPK13 (p38δ MAPK)
Beyond the preview
Go deeper on siRNA MAPK13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA MAPK13.